Major histocompatibility class I (MHC I) molecules bind peptides derived from a cell's
expressed genes and then transport and display this antigenic information on the cell …

Over the past decade, the emergence of effective immunotherapies has revolutionized the
clinical management of many types of cancers. However, long-term durable tumour control …

Immunotherapy has become a key therapeutic strategy in the treatment of many cancers. As
a result, research efforts have been aimed at understanding mechanisms of resistance to …

In recent years, major advances have been made in cancer immunotherapy. This has led to
significant improvement in prognosis of cancer patients, especially in the hematological …

Highlights•Cancers often escape immune control by inactivating MHC-I antigen
presentation.•Immune evasion can arise from lesions in multiple antigen presentation …

The introduction of novel immunotherapies has significantly transformed the treatment
landscape of genitourinary (GU) cancers, even becoming the standard of care in some …

Despite the success of immune checkpoint inhibition (ICI) in treating cancer, patients with
triple-negative breast cancer (TNBC) often develop resistance to therapy, and the underlying …

Despite decades of clinical and preclinical studies, the markers and mechanisms of
resistance to cancer immunotherapy, particularly immune checkpoint blockade (ICB), remain …

Neuroblastoma grows within an intricate network of different cell types including epithelial,
stromal and immune cells. The presence of tumor-infiltrating T cells is considered an …

Background Immunotherapy in high-risk neuroblastoma (HR-NBL) does not live up to its full
potential due to inadequate (adaptive) immune engagement caused by the extensive …